drugset / Trial / NCT00433875

Phase 2 AMG 714 in Rheumatoid Arthritis

NCT00433875 ↗

Phase 2 Completed 180 enrolled Amgen
RandomizedParallel-groupDouble-blindTreatment

Summary

Twelve week treatment of AMG 714 in RA patients who failed at least one DMARD, followed by a 3 month observational period.

Timeline

Start
2002-12
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject ORDESEKIMAB Monoclonal antibody — —

Indications